NCT06285448View on ClinicalTrials.gov

Feasibility of Lecanemab Registry and Clinical Outcome Measures

Enrolling by invitationOBSERVATIONAL

Enrollment

20

Participants

Timeline

Start Date

January 2, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

Alzheimer Disease

Interventions

DRUG

Lecanemab

Bi-weekly infusions of lecanemab \[exposure\].

Trial Locations (1)

55130

HealthPartners Neuroscience Center, Saint Paul

All Listed Sponsors

lead

HealthPartners Institute

OTHER